DK168029B1 - Anvendelse af alfuzosin til fremstilling af laegemidler - Google Patents
Anvendelse af alfuzosin til fremstilling af laegemidler Download PDFInfo
- Publication number
- DK168029B1 DK168029B1 DK246586A DK246586A DK168029B1 DK 168029 B1 DK168029 B1 DK 168029B1 DK 246586 A DK246586 A DK 246586A DK 246586 A DK246586 A DK 246586A DK 168029 B1 DK168029 B1 DK 168029B1
- Authority
- DK
- Denmark
- Prior art keywords
- alfuzosin
- urethra
- alfuzosine
- preparation
- bladder
- Prior art date
Links
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 title claims description 25
- 238000002360 preparation method Methods 0.000 title description 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 229960004607 alfuzosin Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 description 9
- 230000027939 micturition Effects 0.000 description 8
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 6
- 229960001802 phenylephrine Drugs 0.000 description 6
- 229960001289 prazosin Drugs 0.000 description 5
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 206010033892 Paraplegia Diseases 0.000 description 3
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 3
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000005070 sphincter Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000026723 Urinary tract disease Diseases 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001670 myorelaxant effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8507950 | 1985-05-28 | ||
| FR8507950A FR2582513B1 (fr) | 1985-05-28 | 1985-05-28 | Compositions pharmaceutiques contenant de l'alfuzosine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK246586D0 DK246586D0 (da) | 1986-05-27 |
| DK246586A DK246586A (da) | 1986-11-29 |
| DK168029B1 true DK168029B1 (da) | 1994-01-24 |
Family
ID=9319589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK246586A DK168029B1 (da) | 1985-05-28 | 1986-05-27 | Anvendelse af alfuzosin til fremstilling af laegemidler |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4661491A (enExample) |
| EP (1) | EP0204597B1 (enExample) |
| JP (1) | JPS61277620A (enExample) |
| AU (1) | AU586684B2 (enExample) |
| CA (1) | CA1261755A (enExample) |
| DE (1) | DE3683318D1 (enExample) |
| DK (1) | DK168029B1 (enExample) |
| FR (1) | FR2582513B1 (enExample) |
| HU (1) | HUT46221A (enExample) |
| IE (1) | IE58595B1 (enExample) |
| IL (1) | IL78934A (enExample) |
| ZA (1) | ZA863957B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2694495B1 (fr) * | 1992-08-05 | 1994-09-23 | Synthelabo | Préparation pharmaceutique transdermique contenant de l'alfuzosine. |
| DE69333594D1 (de) * | 1992-09-25 | 2004-09-23 | Synaptic Pharma Corp | Für menschliche alpha-1-adrenerge rezeptoren kodierende dns und ihre verwendung |
| WO1994008040A1 (en) * | 1992-09-25 | 1994-04-14 | Synaptic Pharmaceutical Corporation | Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| WO1994009371A1 (en) * | 1992-10-09 | 1994-04-28 | Massachusetts Institute Of Technology | Antemortem diagnostic test for alzheimer's disease |
| JPH07206857A (ja) * | 1993-12-28 | 1995-08-08 | Synthelabo Sa | アルフゾシン塩酸塩の二水和物 |
| FR2717388B1 (fr) * | 1994-03-21 | 1996-11-22 | Synthelabo | Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine. |
| US5503843A (en) * | 1994-04-22 | 1996-04-02 | Flora Inc. | Transdermal delivery of alpha adrenoceptor blocking agents |
| EP0865280A1 (en) * | 1995-11-15 | 1998-09-23 | Merck & Co., Inc. | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS |
| FR2752737B1 (fr) * | 1996-08-29 | 1998-10-02 | Synthelabo | Comprime a liberation controlee de chlorhydrate d'alfuzosine |
| KR100364328B1 (ko) * | 1996-08-29 | 2002-12-26 | 사노피-신델라보 | 알푸조신 염산염의 제어방출 정제 |
| US5922722A (en) * | 1996-11-12 | 1999-07-13 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
| US6214832B1 (en) | 1997-06-18 | 2001-04-10 | Merck & Co., Inc. | Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists |
| US6376503B1 (en) | 1997-06-18 | 2002-04-23 | Merck & Co., Inc | Alpha 1a adrenergic receptor antagonists |
| US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| US6057350A (en) * | 1997-06-18 | 2000-05-02 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| US6143750A (en) * | 1997-06-18 | 2000-11-07 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| AU5234899A (en) | 1998-07-30 | 2000-02-21 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| AU1808400A (en) | 1998-10-29 | 2000-05-22 | Merck & Co., Inc. | Dihydropyridinones and pyrrolinones useful as alpha 1a adrenoceptor antagonists |
| US6228870B1 (en) | 1998-11-10 | 2001-05-08 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1a adrenoceptor antagonists |
| US6319932B1 (en) | 1998-11-10 | 2001-11-20 | Merck & Co., Inc. | Oxazolidinones useful as alpha 1A adrenoceptor antagonists |
| WO2000029386A1 (en) | 1998-11-12 | 2000-05-25 | Merck & Co., Inc. | Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists |
| US6358959B1 (en) | 1999-01-26 | 2002-03-19 | Merck & Co., Inc. | Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists |
| GB2355456A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| GB2355263A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists |
| GB2355264A (en) | 1999-09-30 | 2001-04-18 | Merck & Co Inc | Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists |
| GB2355457A (en) | 1999-09-30 | 2001-04-25 | Merck & Co Inc | Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists |
| US20070105880A1 (en) * | 2005-11-08 | 2007-05-10 | Torrent Pharmaceuticals Limited | Process for the preparation of alfuzosin |
| US20090069562A1 (en) * | 2005-12-26 | 2009-03-12 | Joseph Prabahar Koilpillai | Process for the preparation of alfuzosin |
| WO2008073388A2 (en) * | 2006-12-11 | 2008-06-19 | Mutual Pharmaceutical Company, Inc. | Alfuzosin formulations, methods of making and methods of use |
| US20100092556A1 (en) * | 2006-12-11 | 2010-04-15 | Kristin Arnold | Alfuzosin formulations, methods of making, and methods of use |
| EP2042179A1 (en) * | 2007-09-26 | 2009-04-01 | sanofi-aventis | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
| WO2010083360A2 (en) * | 2009-01-16 | 2010-07-22 | Mutual Pharmaceutical Company, Inc. | Controlled-release formulations |
| MX361757B (es) | 2011-09-19 | 2018-12-13 | Orexo Ab | Nueva composicion farmaceutica resistente al abuso para el tratamiento de la dependencia de opioides. |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| CN113599385B (zh) * | 2021-08-20 | 2023-01-03 | 兰州大学 | 阿夫唑嗪在制备治疗糖尿病及其并发症药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2466462A2 (fr) * | 1978-02-06 | 1981-04-10 | Synthelabo | Derives d'alkylenediamines, leur preparation et leur application en therapeutique |
| FR2421888A1 (fr) * | 1978-02-06 | 1979-11-02 | Synthelabo | Amides d'alkylene-diamines et leur application en therapeutique |
| US4287341A (en) * | 1979-11-01 | 1981-09-01 | Pfizer Inc. | Alkoxy-substituted-6-chloro-quinazoline-2,4-diones |
| GB8320958D0 (en) * | 1983-08-03 | 1983-09-07 | Pfizer Ltd | Quinazoline cardiac stimulants |
-
1985
- 1985-05-28 FR FR8507950A patent/FR2582513B1/fr not_active Expired
-
1986
- 1986-05-12 EP EP86401001A patent/EP0204597B1/fr not_active Expired - Lifetime
- 1986-05-12 DE DE8686401001T patent/DE3683318D1/de not_active Expired - Lifetime
- 1986-05-25 IE IE139586A patent/IE58595B1/en not_active IP Right Cessation
- 1986-05-27 DK DK246586A patent/DK168029B1/da not_active IP Right Cessation
- 1986-05-27 CA CA000510060A patent/CA1261755A/en not_active Expired
- 1986-05-27 JP JP61123220A patent/JPS61277620A/ja active Granted
- 1986-05-27 AU AU57951/86A patent/AU586684B2/en not_active Expired
- 1986-05-27 ZA ZA863957A patent/ZA863957B/xx unknown
- 1986-05-27 HU HU862227A patent/HUT46221A/hu unknown
- 1986-05-27 IL IL78934A patent/IL78934A/xx not_active IP Right Cessation
- 1986-05-27 US US06/867,031 patent/US4661491A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DK246586D0 (da) | 1986-05-27 |
| HUT46221A (en) | 1988-10-28 |
| EP0204597A2 (fr) | 1986-12-10 |
| JPH0564930B2 (enExample) | 1993-09-16 |
| JPS61277620A (ja) | 1986-12-08 |
| ZA863957B (en) | 1987-01-28 |
| CA1261755A (en) | 1989-09-26 |
| AU586684B2 (en) | 1989-07-20 |
| FR2582513B1 (fr) | 1988-08-05 |
| IE861395L (en) | 1986-11-28 |
| DK246586A (da) | 1986-11-29 |
| FR2582513A1 (fr) | 1986-12-05 |
| DE3683318D1 (de) | 1992-02-20 |
| IL78934A (en) | 1991-01-31 |
| EP0204597B1 (fr) | 1992-01-08 |
| AU5795186A (en) | 1986-12-04 |
| US4661491A (en) | 1987-04-28 |
| IL78934A0 (en) | 1986-09-30 |
| EP0204597A3 (en) | 1989-08-16 |
| IE58595B1 (en) | 1993-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK168029B1 (da) | Anvendelse af alfuzosin til fremstilling af laegemidler | |
| US9980927B2 (en) | Use of tapentadol for inhibiting and/or treating depression and anxiety | |
| US7288558B2 (en) | Pharmaceutical composition for treatment for urinary diseases comprising LPA receptor regulator | |
| JP5312027B2 (ja) | 病気の治療法 | |
| US20080234230A1 (en) | Pharmaceutical Composition for Regulation of Pancreatic Juice Secretion Comprising a LPA Receptor Modulator | |
| EP3638232B1 (en) | Tinostamustine for use in treating sarcoma | |
| CN107625762B (zh) | 萘环类药物的新用途 | |
| US7713984B2 (en) | Pharmaceutical uses | |
| RU2496497C1 (ru) | Фармацевтическая композиция для профилактики или лечения ревматоидного артрита, содержащая ребамипид | |
| RU2423692C2 (ru) | Вещества для профилактики и лечения панкреатита | |
| WO2008106536A1 (en) | Use of silodosin in a once daily administration for treating benign prostatic hyperplasia | |
| EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
| NO326446B1 (no) | Anvendelse av deoksypeganin, som fri base eller som et syreaddisjonssalt, for fremstilling av et medikament til behandling av klinisk depresjon | |
| CN120659601A (zh) | 用于治疗瘙痒的诺卡酮 | |
| Smyth et al. | A Method for Measuring Swelling of Hands and Feet Part II: Influence of New Anti-Inflammatory Drug, Indomethacin, in Acute Gout | |
| KR101052804B1 (ko) | 과활동방광을 치료하기 위한 페녹시아세트산 유도체의 사용 | |
| JP2001513497A (ja) | 胃分泌過多および腎損傷の予防作用を有する抗炎症剤の製造のための化合物２−メトキシフェニル−１−メチル−５ｐ−メチルベンゾイル−ピロール−２−アセトアミドアセテートの使用 | |
| US20250375424A1 (en) | Tinostamustine for use in treating sarcoma | |
| JP2002527377A (ja) | β３−アゴニスト活性を有する化合物の新規な治療への使用 | |
| CN106309443B (zh) | 二苯甲烷类药物的用途 | |
| CN106214670B (zh) | 酰胺类药物的用途 | |
| US20110152268A1 (en) | Novel pharmaceutical composition for treating nociceptive pain | |
| WO2005058326A1 (en) | USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs) | |
| WO2007018234A1 (ja) | 尿道内圧上昇作用剤 | |
| KR20190031122A (ko) | 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PUP | Patent expired |